Lucid picked up the award for Excellence in Rare Diseases and Orphan Drugs at this year’s PMEA Awards, which were hosted in London earlier this week.
The agency’s ‘EIDON’ project for AbbVie developed a specialist network and increased the number of specialist centres to advance outcomes of patients with hidradenitis suppurativa (HS).
AbbVie employees, with support from Lucid Group, developed small-group, in clinical training sessions and out of the 62 delegates, 26 of them are establishing new centres, advancing the quality of care in 7,300 patients per year.
PMEA’s judges said: “The Eidon project took a whole programme approach, building awareness from zero to create a network and care delivery infrastructure.
“It is a clearly-structured entry with key behaviours and outcomes defined and measured, and most important, an impressive number of patients were treated.”
Narrowly missing first place, but still achieving a highly commended status on the night was Amicus Therapeutics UK for its work on rare diseases.
Judges said: “Amicus did a very good job for a small outfit in the start-up phase and they showed an extraordinary understanding of payers.”
Run by PMLiVE’s publisher the PMGroup, PMEA exists to reward responsible customer-centric business practices that ensure treatments and advice provide patients with meaningful outcomes.
The programme has been specifically designed to recognise and commend excellence, best practice and innovation in local, European and international markets.
* See all the results from PMEA 2017
* View the PMEA 2017 photo gallery